A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Completed · Phase 4

Conditions studied: Hyperphosphatemia, End Stage Renal Disease

In brief

The study is designed to evaluate the ability of tenapanor alone or in combination with sevelamer to achieve serum phosphorus concentration (sP) within the population reference range (sP \>2.5 and ≤4.5 mg/dL) in patients with end-stage renal disease (ESRD) on dialysis with hyperphosphatemia (\>4.5 mg/dL).

Key facts

Study ID

NCT03988920

Run by

Ardelyx

People needed

172

Starts

2019-06-15

Expected to finish

2021-07-31

Last updated by the study team

2023-03-29

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must complete TEN-02-301 (PHREEDOM)

You may not qualify if…

• Schedlued for kidney transplant
• Life expectancy <12 months

Where it is running

• Ardelyx Site #509 — Houston, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.